Pharmaceuticals

Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.

- Bioeq agreement brings promise of their leading Lucentis® biosimilar for the treatment of retinopathies one step nearer for U.S. patients - ZÜRICH, Nov. 7, 2019 /PRNewswire/ -- Bioeq IP AG ("Bioeq") today announced that it signed a license and development agreement with Coherus BioSciences, In...

2019-11-07 05:14 508

Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

SHANGHAI and LONDON, Nov. 7, 2019 /PRNewswire/ -- Antengene Corporation today announced that it has entered into a licensing agreement with AstraZeneca (LSE/STO/NYSE: AZN) under which Antengene has been granted the exclusive global rights to further develop and commercialize AZD0364. Antengene Co...

2019-11-07 01:40 628

Henlius HLX01 (Rituximab Injection) Wins "Biosimilar Initiative of the Year" at Global Generics & Biosimilars Awards 2019

SHANGHAI, Nov. 7, 2019 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), a leading biopharmaceutical company inChina focusing on oncology and autoimmune diseases, won the award of "Biosimilar Initiative of the Year" (HLX01, rituximab injection) and was also shortlisted for the award of "t...

2019-11-07 01:00 494

Polynoma Presenting Interim Phase III Data for Its Investigational Melanoma Vaccine, Seviprotimut-L, at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

-- MAVIS Study Identifies Most Responsive Patient Subpopulations, Supporting the Continued Study of Adjuvant Treatment in Localized Melanoma Patients -- SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Polynoma LLC, a U.S. immuno-oncology focused biopharmaceutical company and wholly-owned subsidiary ofHon...

2019-11-06 20:00 4938

SHL Celebrates Grand Opening of its Liufu Site in Taoyuan, Taiwan

    TAOYUAN, Taiwan, Nov. 6, 2019 /PRNewswire/ -- On November 5, SHL Group, a global leader in the design, development, and manufacturing of drug delivery devices, held the inauguration of its new Liufu site in Taoyuan City,Taiwan. SHL’s ...

2019-11-06 19:00 492

EpiVax Announces Publication of Antigen-Specific Tolerance Induction by Tregitope in Nature Scientific Reports

PROVIDENCE, Rhode Island, Nov. 6, 2019 /PRNewswire/ -- EpiVax, Inc. ("EpiVax"), a pioneer in immunoinformatics innovation, announces the publication of "Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction" inS...

2019-11-06 18:01 388

Nanoform Wins the CPhI Excellence in Pharma Award for Formulation

HELSINKI, Nov. 6, 2019 /PRNewswire/ -- Nanoform, an innovative medicine enabling nanotechnology company, has won the Excellence in Pharma Award for Formulation at the prestigious CPhI Pharma Awards. Receiving this highly contested prize is an acknowledgement of Nanoform's commitment to innovation...

2019-11-06 17:21 368

15 Years of P-MEC China Driving Global Pharma Technology Forward in China

SHANGHAI, Nov. 6, 2019 /PRNewswire/ -- P-MEC China , co-organized by Informa Markets, CCCMHPIE and Sinoexpo Informa Markets, will take place at the Shanghai New International Expo Center (SNIEC) from June 22-24, 2020. The event will be co-located with CPhI China with ...

2019-11-06 14:00 420

Inovio Demonstrates 80% 6-Month Progression-Free Survival In Phase 2 Glioblastoma Multiforme (GBM) Study with INO-5401 In Combination with PD-1 Inhibitor Libtayo® (cemiplimab)

80% of Methylated Patients and 75% of Unmethylated Patients Were Disease Progression-Free at 6 Months PLYMOUTH MEETING, Pennsylvania, Nov. 5, 2019 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today positive interim results from Inovio's Phase 2 study (NCT03491683) of newl...

2019-11-05 21:00 890

Samsung Biologics and Ichnos Sciences Announce Agreement for Manufacture of ISB 830

INCHEON, South Korea, Nov. 4, 2019 /PRNewswire/ -- Samsung Biologics announced the signing of a long-term agreement with Ichnos Sciences for manufacturing drug substance for ISB 830, an anti-OX40 monoclonal antibody in development as a potential treatment for moderate-to-severe atopic dermatitis....

2019-11-05 08:22 329

Health Charities Benefit from Nationwide Fundraising Campaign

SYDNEY, Nov. 5, 2019 /PRNewswire/ -- AFT Pharmaceuticals is getting behind three charities in a bid to help them raise vital funding for vulnerable Aussies - and get people talking about health. The company's founder and CEO, Hartley Atkinson says the initiative is an opportunity to give back to...

2019-11-05 05:30 449

Luye Pharma's LY03004 Manufacturing Facility Successfully Passes U.S. FDA Pre-approval Inspection with Zero Observation

SHANGHAI, Nov. 4, 2019 /PRNewswire/ -- LY03004, Luye Pharma's innovative, independently developed Extended-Release Microspheres for Injection has taken another step closer to going on the U.S. market. The company has announced that it has received the Establishment Inspection Report from the U.S....

2019-11-05 00:39 376

Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®

- Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease - Alliance to continue to include three product families – empagliflozin, linagliptin and insulin glargine INGELHEIM, Germany, and INDIANAPOLIS,...

2019-11-04 22:00 2881

China Biologic Products to Report Third Quarter 2019 Financial Results

BEIJING, Nov. 4, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company plans to release its third quarter 2019 financial results o...

2019-11-04 21:30 6065

Healthcare Support Remains Strong For Singaporeans With Advanced Breast Cancer, But Patients Call For Greater Disease Education, Survey Finds

* The survey aims to better understand the lives of women living with advanced breast cancer and seeks to provide support to these women around the globe.[1] * With new and better treatments, patients with advanced breast cancer are now living longer and better than before SINGAPORE, Nov. 4, ...

2019-11-04 08:15 465

Encore Medical Education Will Publish the Official Best of SABCS(R) News From the 2019 San Antonio Breast Cancer Symposium (SABCS(R)) Starting December 12, 2019

SAN ANTONIO, Texas, Nov. 1, 2019 /PRNewswire/ -- Encore Medical Education ( www.encoremeded.com ) will publish the Official SABCS® News highlighting the key findings presented at the 42nd San Antonio Breast Cancer Symposium (SABCS®), held on December 10-14, 2019 in San...

2019-11-01 23:00 1152

High Performance Swine Production With Reduced Use of Antibiotics: Second Workshop by EW Nutrition and OPP Group

From 4 to 7 November, in Lleida, Spain, OPP Group and EW Nutrition are hosting their second workshop on animal health and welfare with reduced antibiotic use LLEIDA, Spain, Nov. 1, 2019 /PRNewswire/ -- The two-day event offers swine producers and other stakeholders essential, actionable informati...

2019-11-01 20:22 1127

Dachser Air & Sea Logistics certified for pharmaceutical shipments on three continents

KEMPTEN, Germany, Nov. 1, 2019 /PRNewswire/ -- Following Frankfurt, Mumbai, and Hyderabad, Atlanta is now Dachser's fourth location to receive certification in ten months, further expanding the company's network services for its customers in the life science and healthcare sector.

2019-11-01 09:00 642

Mallinckrodt and Terumo BCT Announce UVADEX® (Methoxsalen) Approved in Australia for use with the THERAKOS® CELLEX® Photopheresis System for the Treatment of Chronic Graft Versus Host Disease (cGvHD) and Skin Manifestations of Cutaneous T-Cell Lymphoma (CTCL) in Adults

SYDNEY, Nov. 1, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, and Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, today announced that UVADEX®  (methoxsalen) has received regulatory approval inAustralia by th...

2019-11-01 04:35 5534

Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCA

GERMANTOWN, Maryland, Oct. 31, 2019 /PRNewswire/ -- Seneca Biopharma, Inc., (Nasdaq: CUR), a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need, will begin trading on the Nasdaq Capital Market under the ticker symbol, NASDAQ: SNCA beginning onN...

2019-10-31 23:00 4070
12345 ... 100